Dan Benjamin Teleman
Known title: Chief Executive OfficerCIK: 0002122500
Dan Benjamin Teleman's purchase track record
Dan Benjamin Teleman has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/17/2026 | NSRX | $20K | +12.3% | pending | — |
| 4/22/2026 | NSRX | $11K | -25.2% | pending | — |
| 3/31/2026 | NSRX | $31K | +57.7% | +60.8% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NSRX | ▲ Buy | Open Market | 6,550 | $20K | 6/17/2026 | View on chart |
| NSRX | ▲ Buy | Open Market | 2,900 | $11K | 4/22/2026 | View on chart |
| NSRX | ▲ Buy | Open Market | 15,000 | $31K | 3/31/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Nasus Pharma Enrolls First Patient in Phase 1 NS003 Study
Nasus Pharma has announced the enrollment and dosing of the first patient in a Phase 1 clinical study for NS003, an intranasal formulation of ondansetron. This marks a key early-stage milestone for the company's development pipeline. The stock is currently trading near its 52-week high, reflecting ongoing interest in these clinical updates.
Nasus Pharma Enrolls First Patient in Phase 1 NS003 Study. Nasus Pharma has announced the enrollment and dosing of the first patient in a Phase 1 clinical study for NS003, an intranasal formulation of ondansetron. This marks a key early-stage milestone for the company's development pipeline. The stock is currently trading near its 52-week high, reflecting ongoing interest in these clinical updates.